Pharma Intelligence

In-depth, multi-region pharmaceutical intelligence search and synthesis, plus drug repurposing, target discovery, clinical evidence review, and bioactivity analysis. Use this skill whenever the user asks about drug approvals, clinical trials, regulatory submissions, pipeline assets, patent landscapes, competitive intelligence, scientific evidence, disease targets, genetic associations, or compound bioactivity for any drug, target, indication, or company — especially when coverage of China, US, Europe, Japan, South Korea, or Australia is needed. Trigger even for casual queries like "what's the approval status of X in China", "find trials for Y in Japan", "compare pipeline coverage across regions", "find drugs for disease Z", or "what targets are associated with condition W". Always consult this skill before answering any pharma or biomedical research question that requires source-grounded data.

Global Pharma Intelligence & Biomedical Research Skill

Systematic, source-prioritized search and synthesis across regulatory, clinical, academic, and commercial databases — covering all major pharmaceutical markets and 14+ biomedical research databases.

MCP Server — How to Invoke

There is no dedicated MCP tool in your toolbox. Call the unified endpoint over HTTP via web_fetch (POST) or run_in_terminal (curl):

https://mcp.sciminer.tech/tools/unified/mcp

Every call is a JSON-RPC POST. Always set Content-Type: application/json and Accept: application/json.

curl -X POST https://mcp.sciminer.tech/tools/unified/mcp \
  -H "Content-Type: application/json" -H "Accept: application/json" \
  -d '{"jsonrpc":"2.0","method":"tools/call","params":{"name":"ctg_search_studies","arguments":{"intervention":"pan-RAS","condition":"cancer","max_results":20}},"id":1}'

See references/mcp-tools.md for every tool's parameters and return shape.

---

Core Principle: Tiered Source Priority

Every region follows a 3-tier hierarchy. Higher tiers override lower-tier claims; always cite the tier.

Tier	Type	Description
Tier 1	Regulatory	Official agency submissions, approvals, labels
Tier 2	Trial registries	Prospective/registered clinical evidence
Tier 3	Academic / IP	Published papers, conferences, patents

For the per-region source map (CN / US / EU / JP / KR / AU + global) with URLs and access notes, see references/sources-by-region.md.

---

Search Workflow

Step 1 — Classify the Query (pick ONE intent)

#	Intent	Trigger phrases
A	Trial landscape	"trials of X", "clinical studies of", "who is testing", "phase 2/3 of"
B	Approval / regulatory status	"is X approved", "approval status", "FDA/EMA/NMPA cleared"
C	Safety / adverse events	"side effects of", "is X safe", "adverse events", "black box"
D	Pipeline / competitive intel	"pipeline", "competitive landscape", "who else is developing"
E	Patent / IP / exclusivity	"when does patent expire", "patent landscape", "exclusivity"
F	Target / mechanism / drug discovery	"drugs targeting X", "mechanism of", "bioactivity", "IC50"
G	Repurposing / target discovery	"repurpose for", "targets associated with disease", "genetic basis"
H	Literature / evidence review	"recent papers on", "what's known about", "systematic review"

Also capture: regions in scope (US / EU / JP / CN / KR / AU / global) and time horizon.

Step 2 — Execute the Per-Intent Sequence

Run the workflow for the chosen intent (see Per-Intent Workflows) in order. For sources without MCP coverage (CN NMPA/CDE, EMA EPAR, PMDA, jRCT, CTIS, CRIS, ANZCTR, Orange Book), use web_fetch only at the steps that name them.

Resolve identifiers as needed:

• Free-text disease → MONDO/EFO ID via opentargets_search
• Free-text gene → HGNC symbol via mygene_search_genes
• Cross-database ID conversion → nodenorm_get_normalized_nodes

Step 3 — Resolve Conflicts

1. Higher-tier source wins (Tier 1 > Tier 2 > Tier 3).
2. More recent data wins within the same tier.
3. Flag unresolved conflicts; do not silently pick one.

Step 4 — Synthesize and Present

Structure output to match the intent of the question:

• Trial landscape → table of trials (NCT/registry ID, phase, status, sponsor, N, primary endpoint).
• Approval status → region × status × date × indications table.
• Safety → top FAERS reactions plus black-box / warnings.
• Pipeline → drug × company × phase × mechanism table.
• Patent → patent number, jurisdiction, expiry.

Always cite source, tier, and access date.

---

Per-Intent Workflows

A. Trial Landscape

"What clinical studies / trials exist for [drug | target | indication]?"

Default scope = ALL regions. Only narrow if the user names a single region.

ctg_search_studies covers only ClinicalTrials.gov, which is primarily US-registered trials. Run each regional source in parallel.

1. United States — ctg_search_studies via MCP.
   • Use intervention for a drug, condition for a disease, both for combined.
   • For a target/class (e.g., "pan-RAS", "PD-L1 inhibitor"): pass the class term as intervention plus a relevant condition.
   • Then ctg_get_study on top hits for eligibility, endpoints, sponsor, locations.
2. China — web_fetch:
   • http://www.chinadrugtrials.org.cn (mandatory CN IND registry)
   • https://www.chictr.org.cn (ChiCTR, WHO primary)
3. Europe — web_fetch:
   • https://euclinicaltrials.eu (CTIS — current EU register)
   • https://eudract.ema.europa.eu (EudraCT — legacy historical trials)
   • https://www.isrctn.com (ISRCTN, UK/global)
4. Japan — web_fetch:
   • https://jrct.niph.go.jp (jRCT — mandatory JP registry)
   • https://www.umin.ac.jp/ctr/ (UMIN-CTR — legacy)
5. South Korea — web_fetch https://cris.nih.go.kr.
6. Australia / New Zealand — web_fetch https://www.anzctr.org.au.
7. WHO ICTRP catch-all — web_fetch https://trialsearch.who.int for any WHO primary registry (covers India CTRI, Iran IRCT, Brazil ReBEC, etc.). Also europepmc_search via MCP for ICTRP-linked publications.
8. Published results — pubmed_search_articles with NCT ID or drug name to surface completed-trial papers.
9. US company-disclosed pipeline (optional) — edgar_fulltext_search for US-listed sponsors.

For every regional web_fetch: query both INN and brand name; for CN also use the Chinese transliteration (see references/drug-naming.md). Aggregate results in one table with a "Registry" column.

B. Approval / Regulatory Status

"Is [drug] approved in [region]?"

1. US — openfda_search_drug_labels + dailymed_search_drug_labels (label date anchors approval); fda_orphan_search_designations for orphan status.
2. Non-US — web_fetch the regional Tier 1 source (NMPA, EMA EPAR, PMDA, MFDS, TGA). For CN, also search Chinese characters.
3. chembl_get_drug_indications — cross-check approved indications and max phase.
4. Say "not approved" only when Tier 1 affirms denial/withdrawal. Otherwise: "no record found as of [date]".

C. Safety / Adverse Events

1. openfda_search_adverse_events (drug_name, seriousness=serious).
2. openfda_get_drug_label with section="warnings" and section="contraindications".
3. chembl_get_molecule for the black-box warning flag.
4. pubmed_search_articles with keywords: ["adverse effect", "toxicity"] for case reports and post-marketing literature.

D. Pipeline / Competitive Intelligence

"Who else is developing for [indication / target]? What's the global competitive landscape?"

Default scope = ALL regions. A competitive landscape without the active-trial picture is incomplete, so run the full multi-region trial sweep from Workflow A and then layer pipeline-specific sources on top.

1. Active trials — all regions — run Workflow A steps 1–7 in full, optionally adding recruitment_status=RECRUITING (or ACTIVE_NOT_RECRUITING) and a phase filter to focus on competitors at a specific stage.
2. Company disclosures — edgar_fulltext_search for pipeline language in 10-K / 10-Q / 8-K (US-listed sponsors only).
3. Patent activity per company — web_fetch https://patents.google.com with an assignee: filter (or WIPO PATENTSCOPE / Espacenet — see Workflow E).
4. Published results — pubmed_search_articles with NCT IDs or drug names to surface completed-trial papers.

Aggregate into one table: drug × company × phase × mechanism × registry/region.

E. Patent / IP / Exclusivity

All listed patent sources are free and require no API key.

1. Global patent search — web_fetch one or more of:
   • https://patents.google.com (Google Patents — best full-text search, covers USPTO, EPO, WIPO, JPO, CNIPA, KIPO).
   • https://patentscope.wipo.int (WIPO PATENTSCOPE — authoritative for PCT applications and national filings worldwide).
   • https://worldwide.espacenet.com (EPO Espacenet — strongest European and family-tree coverage).
2. US patents (structured) — uspto_ppubs_search_patents via MCP for granted patents and applications.
3. Patent family / cross-jurisdiction equivalents — Espacenet's "INPADOC patent family" view, or Google Patents' "Worldwide applications" section.
4. Orange Book (patent + exclusivity expiry for FDA-approved drugs) — web_fetch https://www.accessdata.fda.gov/scripts/cder/ob.
5. Orphan exclusivity — fda_orphan_search_exclusivity (7-year US orphan exclusivity).

F. Target / Mechanism / Drug Discovery

1. chembl_find_drugs_by_target (target_name = gene symbol, include_all_mechanisms=true).
2. chembl_get_mechanism for each candidate.
3. chembl_get_activities — IC50 / Kd / EC50 for bioactivity comparisons.
4. uniprot_search_proteins — protein function and druggability.
5. reactome_search_pathways or kegg_find_pathways — pathway context.

G. Repurposing / Target Discovery

1. opentargets_search (entity_type="disease") → MONDO ID.
2. opentargets_get_associations (disease_id, size 20–30) → ranked targets by evidence score.
3. gwas_search_associations — variants linking targets to disease.
4. omim_search_entries — Mendelian basis (requires API key).
5. For each top target: chembl_find_drugs_by_target (include_all_mechanisms=true).
6. ctg_search_studies with each drug as intervention for prior-art trials.
7. openfda_search_adverse_events as a safety filter for non-trivial candidates.

H. Literature / Evidence Review

1. pubmed_search_articles — entry point; use diseases, chemicals, genes for entity-aware filtering.
2. europepmc_search — broader: grants, preprints, non-MEDLINE.
3. europepmc_search_preprints — bioRxiv / medRxiv only.
4. pubmed_get_article — abstract or full text for top hits.

---

Combination Strategies (cross-intent)

Use only when a question genuinely spans multiple intents.

• Disease → Targets → Drugs → Trials: opentargets_search → opentargets_get_associations → chembl_find_drugs_by_target → ctg_search_studies
• Gene → Protein → Pathways → Drugs: mygene_search_genes → uniprot_get_protein → reactome_search_pathways → chembl_find_drugs_by_target
• Variant → Gene → Disease → Treatments: myvariant_get_variant → mygene_get_gene → omim_search_entries → chembl_find_drugs_by_target
• Drug → Safety → Label → Trials: chembl_get_mechanism → openfda_search_adverse_events → openfda_get_drug_label → ctg_search_studies

---

API Keys

Most APIs require no key. Exceptions:

Database	Key	Source
OMIM	Required	https://omim.org/api
NCI Clinical Trials	Optional	https://clinicaltrialsapi.cancer.gov
OpenFDA	Optional (higher rate limits)	https://open.fda.gov/apis

All others (ChEMBL, OpenTargets, PubMed, ClinicalTrials.gov, Reactome, KEGG, UniProt, GWAS, Pathway Commons, MyGene / MyVariant / MyChem, Node Normalization, USPTO PPUBS) are public. Patent landscape work uses Google Patents, WIPO PATENTSCOPE, and Espacenet via web_fetch — no keys required.

---

Output Quality Standards

• Never fabricate approval dates, trial IDs, or efficacy numbers.
• Attribute every claim to its source and tier.
• Flag gaps explicitly (e.g., "No registered trials found in jRCT as of [date]").
• Distinguish "no data found" from "not approved" — absence of evidence ≠ negative regulatory decision.
• For Chinese sources: note whether the search was conducted in Chinese characters; romanization alone may miss records.

---

Troubleshooting

No results?

• Try alternative terms (INN vs brand name, gene symbol vs protein name).
• Use standardized IDs: MONDO for diseases, HGNC for genes, ChEMBL IDs for compounds, Ensembl for OpenTargets.
• Convert IDs across databases with nodenorm_get_normalized_nodes.

Too many results?

• Add filters: max_results, phase, recruitment_status, reviewed (UniProt).
• Apply date ranges where supported.

API key errors?

• OMIM requires a key; NCI and OpenFDA accept optional keys for higher rate limits.

Source not covered by MCP?

• Fall back to web_fetch for CDE/NMPA, EMA/EPAR, PMDA, jRCT, CTIS, CRIS, ANZCTR, Orange Book.

---

References

• references/mcp-tools.md — Parameters and call format for every MCP tool.
• references/drug-naming.md — INN / brand / Chinese / Japanese naming conventions and transliteration.
• references/regulatory-timelines.md — Review-clock lengths and milestones per agency (FDA, EMA, PMDA, CDE/NMPA, etc.).
• references/sources-by-region.md — Direct URLs and access notes for all regional regulatory databases.
• references/pharma-intelligence-workflow.md — End-to-end worked example with curl commands (osimertinib in NSCLC).